Your browser doesn't support javascript.
loading
Stable Protein Sialylation in Physcomitrella.
Bohlender, Lennard L; Parsons, Juliana; Hoernstein, Sebastian N W; Rempfer, Christine; Ruiz-Molina, Natalia; Lorenz, Timo; Rodríguez Jahnke, Fernando; Figl, Rudolf; Fode, Benjamin; Altmann, Friedrich; Reski, Ralf; Decker, Eva L.
Afiliação
  • Bohlender LL; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Parsons J; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Hoernstein SNW; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Rempfer C; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Ruiz-Molina N; Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, Germany.
  • Lorenz T; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Rodríguez Jahnke F; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Figl R; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Fode B; Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, Germany.
  • Altmann F; Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria.
  • Reski R; Eleva GmbH, Freiburg, Germany.
  • Decker EL; Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria.
Front Plant Sci ; 11: 610032, 2020.
Article em En | MEDLINE | ID: mdl-33391325
ABSTRACT
Recombinantly produced proteins are indispensable tools for medical applications. Since the majority of them are glycoproteins, their N-glycosylation profiles are major determinants for their activity, structural properties and safety. For therapeutical applications, a glycosylation pattern adapted to product and treatment requirements is advantageous. Physcomitrium patens (Physcomitrella, moss) is able to perform highly homogeneous complex-type N-glycosylation. Additionally, it has been glyco-engineered to eliminate plant-specific sugar residues by knock-out of the ß1,2-xylosyltransferase and α1,3-fucosyltransferase genes (Δxt/ft). Furthermore, Physcomitrella meets wide-ranging biopharmaceutical requirements such as GMP compliance, product safety, scalability and outstanding possibilities for precise genome engineering. However, all plants, in contrast to mammals, lack the capability to perform N-glycan sialylation. Since sialic acids are a common terminal modification on human N-glycans, the property to perform N-glycan sialylation is highly desired within the plant-based biopharmaceutical sector. In this study, we present the successful achievement of protein N-glycan sialylation in stably transformed Physcomitrella. The sialylation ability was achieved in a Δxt/ft moss line by stable expression of seven mammalian coding sequences combined with targeted organelle-specific localization of the encoded enzymes responsible for the generation of ß1,4-galactosylated acceptor N-glycans as well as the synthesis, activation, transport and transfer of sialic acid. Production of free (Neu5Ac) and activated (CMP-Neu5Ac) sialic acid was proven. The glycosidic anchor for the attachment of terminal sialic acid was generated by the introduction of a chimeric human ß1,4-galactosyltransferase gene under the simultaneous knock-out of the gene encoding the endogenous ß1,3-galactosyltransferase. Functional complex-type N-glycan sialylation was confirmed via mass spectrometric analysis of a stably co-expressed recombinant human protein.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Plant Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Plant Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha